

# Alternate Therapeutic Strategies for the Reduction of Serum LDL Cholesterol and the Associated Risk of Atherosclerosis

Published date: Feb. 1, 2012

## Technology description

### Description

The invention offers TAT-APOBEC-1 gene therapy for the reduction of serum LDL cholesterol and the associated risk of atherosclerosis. The induction of TAT-APOBEC-1 expression in a limited number of hepatocytes in situ through viral (adenoviral) delivery and its secretion into the local hepatic circulation will result in the local uptake of TAT-APOBEC-1 by liver cells and the induction of Apolipoprotein B (apoB) mRNA editing. Liver cells in which editing have been induced by TAT-APOBEC-1 will produce less apoB100 protein and more apoB48 during the process of VLDL assembly and secretion into serum. The novelty of tagging TAT-APOBEC-1 with secretion signals and creating a hepatic mosaic of expression through adenoviral delivery is that the patient

### Institution

[University of Rochester](#)

## 联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com